BioCryst Elects ex-Glaxo and Squibb Exec to Board
From Associated Press (December 9, 2009)
BIRMINGHAM, Ala.--Flu drug maker BioCryst
Pharmaceuticals Inc. said Wednesday it elected
Charles Sanders to its board of directors.
Sanders worked for five years as CEO of Glaxo Inc., which is now
part of GlaxoSmithKline PLC, and was
chairman of the Glaxo board for three years. He is also a former
vice chairman of Squibb Corp., now part of
Bristol-Myers Squibb Co. His
appointment expands BioCryst's board to eight members.
The U.S. government has approved BioCryst's intravenous flu drug
peramivir as an emergency treatment
for swine flu. The company expects to continue testing peramivir
until 2011 to win full approval. Japanese regulators are reviewing
an application to approve peramivir as an outpatient flu treatment.
Peramivir is intended for patients who are too sick to take an oral
drug.
BioCryst is also testing a drug calledforodesine
as a treatment for three cancers: cutaneous T-cell
lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic
leukemia.
Posted: December 2009
